Type 2 Diabetes
FreeDM2: Real-time CGM for type 2 diabetes on basal insulin.
A UK randomised trial in the largest insulin-treated type 2 cohort that NICE guidelines NG28 doesn't currently fund.
5 days ago
Article Archive
Browse all clinical evidence, news, and expert commentary
Type 2 Diabetes
NG28 NICE GUIDELINES: The Flozin-First Era, and 810,000 More GLP-1 Patients
The February 2026 update to NG28 ends that era. Most newly diagnosed patients will now be offered an SGLT-2 inhibitor alongside metformin from the outset.
5 days ago
Prescribing Safety
SCOUT: what the UTI trial adds to UK primary care prescribing
The SCOUT trial is the first pragmatic head-to-head comparison of all four commonly used UTI regimens in a single trial. The results reinforce rather than redraw the UK prescribing picture — but they do sharpen one key question for primary care.
Medicine Central5 days ago
Prescribing Safety
The safety circuit breaker: redefining the diagnostic journey (Jess's Rule)
The mandate is clear: if a diagnosis remains unsubstantiated or symptoms escalate after three appointments — Reflect, Review, and Rethink. Three strikes and we rethink.
12 days ago
Prescribing Safety
Why CRP testing didn't cut antibiotic prescribing
The PRUDENCE trial tested point-of-care diagnostics across 2,639 patients in 13 countries. It didn't reduce antibiotic prescribing. The reason why matters more than the result.
12 days ago
Women's Health
LDL Elevation in Menopause - Interpreting Lipids in Primary Care
From raised LDL to a new non-hormonal drug class and the largest HRT safety study to date, this week is all menopause in primary care.
12 days ago
AI & Digital Health
AI scribes and the changing shape of clinical documentation
Dr Frederick Reynolds, a GP using ambient scribes day-to-day, has written the kind of thoughtful, first-hand review these tools deserve.
Dr Frederick Reynolds12 days ago
Women's Health
A new non-hormonal choice for hot flushes: NICE approves NK3 RAs
NICE has now recommended the first drug in a genuinely new class — Fezolinetant in TA1143. It's an NK3 receptor antagonist for moderate to severe menopausal vasomotor symptoms when HRT isn't suitable.
12 days ago
Women's Health
The largest HRT mortality study and what it means for UK primary care
No excess mortality after 14 years. No signal for cardiovascular or cancer deaths; plus a survival benefit in women after bilateral oophorectomy.
26 days ago
Chronic Kidney Disease
Falling through the GAAP: when patients diagnose themselves
One in 10 patients surveyed by Kidney Care UK found out they had CKD by seeing it recorded in the NHS App. Almost 40% had no opportunity to discuss the diagnosis with a healthcare professional.
about 1 month ago
Neurology
GLP-1 for Alzheimer's? EVOKE trial says no
The EVOKE trials are in, and the answer is no. Novo Nordisk has terminated the programme and discontinued the planned one-year extension of both trials.
about 1 month ago
Cardiovascular Disease
SGLT2 trial watch
When a patient stops a medication, the assumption is usually that the benefits stop too. The EMPA-KIDNEY post-trial follow-up, published in NEJM, checked if this is true for SGLT2 inhibitors in CKD.
about 1 month ago
Chronic Kidney Disease
The Kidney Failure Risk Equation: who should we refer?
The kidney failure risk equation is now in NICE guidance. A new BJGP study from Greater Manchester found that, for most patients, the risk of death is much higher than the risk of needing dialysis.
about 1 month ago
Cardiovascular Disease
COBRRA delivers the first head-to-head DOAC comparison in VTE
For over a decade, the question of whether to use apixaban or rivaroxaban for treating acute VTE has remained. The COBRA Trial in NEJM finally provides a head-to-head comparison.
about 1 month ago
Cardiovascular Disease
What could the future antihypertensive medication landscape look like?
Low-dose multi-drug pills are key and new ways to tackle resistant hypertension are emerging. Since 2022, many Phase III antihypertensive trials have been reported.
about 2 months ago
Cardiovascular Disease
Statins past 80: what does the evidence actually say?
At what age do you stop offering statins for primary prevention? It's a question the guidelines can only partially answer.
about 2 months ago
Obesity
GLP-1 Receptor Agonists: Mechanism of Action
How GLP-1 receptor agonists drive weight loss across the brain, gut, and metabolism.
about 2 months ago
Chronic Kidney Disease
SGLT2i vs GLP-1 RA: which one offers more kidney protection?
Both SGLT2 inhibitors and GLP-1 receptor agonists protect the kidneys in type 2 diabetes. A large new JAMA study is the closest we have to a head-to-head answer — and the results are not straightforward.
about 2 months ago
Women's Health
The latest evidence (2025–2026) on the benefits and risks of menopausal HRT
Individualised HRT offers substantial symptomatic relief with acceptable safety when used appropriately; however, ongoing research is needed to address persistent uncertainties about long-term outcomes.
about 2 months ago
Primary Care Policy
It shouldn't be this hard!
What the RCGP and Patients Association report means for GP workload, referrals, and NHS digital systems.
2 months ago
Rare Disease
Rare disease in UK primary care: why 'more education' isn't enough
1 in 17 people will be affected by a rare disease in their lifetime. Most will wait years for a diagnosis. The default answer has always been that primary care needs more education — but is that actually true?
2 months ago
AI & Digital Health
Is it science fiction? The NHS just tested a real-life tricorder
Imperial College London just published the results of a trial called TRICORDER, a handheld device that can diagnose conditions without blood tests or waiting lists.
2 months ago
Primary Care Policy
NICE is about to prescribe more medicines — here's why
For 26 years, NICE has used the same yardstick to decide whether a new medicine is worth funding. From April 2026, that yardstick is changing for the first time, and prescribers will feel it.
2 months ago
Public Health
Only 61% of children in one London borough are fully vaccinated by age 5
Childhood vaccination is supposed to be one of the most straightforward public health interventions. So why are rates falling in parts of London?
2 months ago
Page 1